Since several clinical trials already confirmed that testosterone is a safe, feasible, and reasonably well-tolerated therapy for men with early hormone-refractory prostate cancer [39,48,72,73], we believe that manipulating androgen/AR signaling can be a potential therapy for AR-positive advanced prostate cancer. The gene discussed is AR; the disease is prostate cancer.